Trial Profile
An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms VERSIFY
- Sponsors Takeda
- 01 Jul 2022 Results of pooled analysis from NCT01369329, NCT02425111, NCT02096861 and other study comparing the efficacy of adalimumab, infliximab, ustekinumab, and vedolizumab on the ability to achieve endoscopic healing (EH) after 1 year of therapy in moderate-severe Crohns disease, published in the American Journal of Gastroenterology
- 17 May 2022 Results (n=69) assessing a computational approach integrating a mechanistic model of Crohn's disease with a responder classifier to predict temporal changes in mucosal health published in the Advances in Therapy
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020